(Q42252021)

19 October 2017

title

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths (English)

1 reference

19 October 2017

main subject

cervix uterine cancer

1 reference

3

1 reference

19 October 2017

2

Xavier Castellsagué

0 references

author name string

Georges Van Kriekinge

series ordinal

1

1 reference

19 October 2017

Nadia Demarteau

series ordinal

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

26 November 2013

1 reference

19 October 2017

1 reference

19 October 2017

volume

32

1 reference

19 October 2017

issue

6

1 reference

19 October 2017

page(s)

733-739

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

The health care costs of cervical human papillomavirus--related disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.049

10.1016/J.VACCINE.2013.11.049

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference